Vaccinex Inc VCNX

Healthcare Biotechnology

Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.

OTCPK:VCNX - Post by User

Vaccinex Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Aug 14, 2024 12:30pm

388 Views

Post# 36178736

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase

News; $VCNX Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development PartnershipROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer’s disease. Our Company recently announced positive results of the phase 1b/2 study of its ...VCNX - Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

<< Previous

Bullboard Posts

Next >>

Thunder Gold makes generational discovery